Levation Pharma, Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Levation Pharma, Ltd. - overview
Established
2017
Location
Tel Aviv-Yafo, -, Israel
Primary Industry
Pharmaceuticals
About
Based in Tel Aviv, Israel, and founded in 2017 by Houman Hemmati, Levation Pharma, Ltd. operates as a healthcare company that develops therapies for aesthetic and functional eyelid and facial conditions. Levation Pharma, Ltd. raised venture funding from investor Peregrine Ventures.
The firm offers therapies for treating Acquired Blepharoptosis, a condition causing drooping of the upper eyelids. The company’s product line includes medicines for aesthetic dermatology such as the LEV-102, an aqueous gel designed for daily application to the upper eyelids. LEV-102 contains oxymetazoline, which targets Mueller’s muscle to lift the upper lid and improve visual fields and appearance without affecting voluntary eye muscles.
Current Investors
Peregrine Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Dermatology, Pharmaceutical Research & Development
Website
www.levationpharma.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.